INDV
Indivior Pharmaceuticals, Inc.Company Information
- Company Name
- Indivior Pharmaceuticals, Inc.
- CIK
- CIK0001625297
- Category
- Large accelerated filer
- Ticker: Exchange
- INDV: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- INDV
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-27
- Last sale
- 2026-07-10
- Shares purchased (TTM)
- 8,850
- Shares sold (TTM)
- 73,172
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 117,878,365
- Shares outstanding
- 119,000,000
- Ownership
- 99.06%
Earnings Market Reaction
- Filing date
- 2026-08-03
- Price on filing date
- —
- 1-month reaction
- -6.69%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||
| Cash And Cash Equivalents At Carrying Value | 222 | 175 | 195 | 445 | 510 | 372 | 319 | ||||||
| Short Term Investments | - | - | 0 | 0 | 0 | 1 | 1 | ||||||
| Accounts Receivable Net Current | 271 | 273 | 253 | 259 | 240 | 243 | 254 | ||||||
| Inventory Net | 150 | 152 | 153 | 155 | 149 | 163 | 167 | ||||||
| Prepaid Expense Current | 14 | 15 | 34 | 30 | 28 | 56 | 31 | ||||||
| Prepaid Expense And Other Assets Current | - | - | - | - | - | - | 53 | ||||||
| Income Taxes Receivable | 16 | 12 | 2 | 13 | 3 | 29 | 33 | ||||||
| Deposits Assets Current | - | - | - | - | - | - | 0 | ||||||
| Other Assets Current | 54 | 40 | 16 | 19 | 20 | 20 | 21 | ||||||
| Assets Current | 725 | 667 | 652 | 922 | 951 | 883 | 827 | ||||||
| Long Term Investments | 27 | 27 | 28 | 28 | 27 | 27 | 27 | ||||||
| Property Plant And Equipment Net | 162 | 157 | 144 | 124 | 117 | 104 | 100 | ||||||
| Operating Lease Right Of Use Asset | 21 | 22 | 26 | 30 | 35 | 37 | 39 | ||||||
| Intangible Assets Net Including Goodwill | 2 | 2 | 2 | 2 | 7 | 7 | 6 | ||||||
| Deferred Income Tax Assets Net | 271 | 296 | 323 | 285 | 270 | 279 | 277 | ||||||
| Other Assets Noncurrent | 24 | 26 | 27 | 27 | 44 | 39 | 39 | ||||||
| Assets | 1,233 | 1,197 | 1,201 | 1,416 | 1,452 | 1,375 | 1,316 | ||||||
Liabilities Current | |||||||||||||
| Contract With Customer Refund Liability Current | 610 | 551 | 582 | 613 | 709 | 675 | 562 | ||||||
| Accounts Payable And Accrued Liabilities Current | 206 | 178 | 250 | 215 | 196 | 183 | 216 | ||||||
| Litigation Reserve Current | 14 | 14 | 42 | 106 | 105 | 105 | 99 | ||||||
| Long Term Debt Current | 0 | 0 | 29 | 18 | 18 | 18 | 18 | ||||||
| Operating Lease Liability Current | 9 | 9 | 10 | 10 | 11 | 11 | 10 | ||||||
| Accrued Income Taxes Current | 30 | 26 | 2 | 4 | 17 | 12 | 7 | ||||||
| Other Liabilities Current | - | - | 0 | 0 | 0 | 3 | 11 | ||||||
| Liabilities Current | 868 | 779 | 914 | 965 | 1,056 | 1,005 | 924 | ||||||
| Long Term Debt Noncurrent | 487 | 486 | 290 | 304 | 308 | 311 | 315 | ||||||
| Litigation Reserve Noncurrent | 42 | 41 | 52 | 300 | 299 | 297 | 365 | ||||||
| Operating Lease Liability Noncurrent | 13 | 14 | 22 | 24 | 29 | 30 | 32 | ||||||
| Other Liabilities Noncurrent | 31 | 21 | 21 | 30 | 18 | 17 | 18 | ||||||
| Liabilities | 1,441 | 1,341 | 1,300 | 1,623 | 1,709 | 1,660 | 1,652 | ||||||
Stockholders Equity | |||||||||||||
| Common Stock Value | 0 | 0 | 62 | 62 | 62 | 62 | 62 | ||||||
| Additional Paid In Capital | 155 | 165 | 112 | 109 | 101 | 93 | 90 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -28 | -29 | -30 | -32 | -33 | -35 | -36 | ||||||
| Retained Earnings Accumulated Deficit | -334 | -280 | -243 | -346 | -388 | -406 | -443 | ||||||
| Stockholders Equity | -208 | -144 | -98 | -207 | -257 | -285 | -337 | ||||||
| Liabilities And Stockholders Equity | 1,233 | 1,197 | 1,201 | 1,416 | 1,452 | 1,375 | 1,316 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 3 | 3 | 4 | 2 | 2 | 2 | 3 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | ||||||
| Common Stock Shares Issued | 118 | 122 | 125 | 125 | 125 | 125 | 125 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialIndivior Pharmaceuticals, Inc. (INDV) — SEC Financial Statements & Analysis
Indivior Pharmaceuticals, Inc. (INDV) is a pharmaceutical preparations company, incorporated in DE. Indivior Pharmaceuticals, Inc. trades on Nasdaq as: INDV. Indivior Pharmaceuticals, Inc. (INDV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03. Based on that filing, Indivior Pharmaceuticals, Inc. carries a market cap of $4.88B, a P/E ratio of 13.72x, a P/B ratio of -23.47x, a P/S ratio of 3.67x, an enterprise value of $5.15B, and an EV/EBITDA multiple of 11.94x. On profitability, it posts a gross margin of 82.19%, an operating margin of 31.63%, a net margin of 26.75%, a Return on Equity (ROE) of -153.12%, and a Return on Assets (ROA) of 26.52%. Per share, it reports EPS of $2.99, diluted EPS of $2.87, free cash flow per share of $-0.93, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 0.84x, a quick ratio of 0.65x, working capital of $-143.00M, a debt-to-equity ratio of -6.93x, a debt ratio of 1.17, an interest coverage ratio of 15.59x, free cash flow of $-111.00M (TTM), and net debt of $265.00M. Figures sourced from SEC EDGAR.
- Market Cap
- $4.88B
- P/E TTM
- 13.72x
- EPS TTM
- $2.99
- P/B TTM
- -23.47x
- ROE TTM
- -153.12%
- ROA TTM
- 26.52%
- Debt To Equity
- -6.93x
- Free Cash Flow TTM
- $-111.00M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Indivior Pharmaceuticals, Inc. in?
Indivior Pharmaceuticals, Inc. (INDV) operates in the Pharmaceutical Preparations industry.
What exchange does INDV trade on?
Indivior Pharmaceuticals, Inc. (INDV) trades on the Nasdaq.
Where is Indivior Pharmaceuticals, Inc. incorporated?
Indivior Pharmaceuticals, Inc. is incorporated in DE.
When was Indivior Pharmaceuticals, Inc. (INDV)'s most recent SEC filing?
Indivior Pharmaceuticals, Inc. (INDV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03.
What is INDV's market cap?
Indivior Pharmaceuticals, Inc. (INDV) has a market capitalization of $4.88B as of 2026-06-30.
What is INDV's P/E ratio?
Indivior Pharmaceuticals, Inc. (INDV)'s trailing twelve month P/E ratio is 13.72x as of 2026-06-30.
What is INDV's EPS (earnings per share)?
Indivior Pharmaceuticals, Inc. (INDV)'s trailing twelve month EPS is $2.99 as of 2026-06-30.
What is INDV's ROE (return on equity)?
Indivior Pharmaceuticals, Inc. (INDV)'s trailing twelve month Return on Equity (ROE) is -153.12% as of 2026-06-30.
What is INDV's ROA (return on assets)?
Indivior Pharmaceuticals, Inc. (INDV)'s trailing twelve month Return on Assets (ROA) is 26.52% as of 2026-06-30.
What is INDV's EV/EBITDA?
Indivior Pharmaceuticals, Inc. (INDV)'s trailing twelve month EV/EBITDA is 11.94x as of 2026-06-30.